Relmada Therapeutics (RLMD) Misses Q4 EPS by 10c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($0.27), $0.10 worse than the analyst estimate of ($0.17).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• BofA maintains underperform ratings on six BDC stocks
• Is the global equity rally broadening? UBS weighs in
• Lazard Global Total Return fund declares $0.1534 monthly distribution